Jasper Therapeutics (JSPR) Share-based Compensation (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Share-based Compensation of $1.7 million for Q4 2025, down 15.69% year-over-year from $2.0 million in Q4 2024, and down 84.48% quarter-over-quarter from $10.7 million in Q3 2025.
Jasper Therapeutics (JSPR) Share-based Compensation (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Share-based Compensation history runs 6 years deep, the most recent figure standing at $1.7 million for Q4 2025.
- In Q4 2025, Share-based Compensation fell 15.69% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $7.4 million (up 12.49% YoY), while the FY2025 annual figure was $8.9 million, up 34.46% from the prior year.
- Share-based Compensation for Q4 2025 stood at $1.7 million, down from $10.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $15.0 million in Q1 2025, with the low at -$90000.0 in Q4 2022.
- The 5-year median for Share-based Compensation is $1.2 million (2023), against an average of $2.3 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation slumped 138.96% in 2022, then jumped 148100.0% in 2024.
- Jasper Therapeutics' Share-based Compensation stood at $231000.0 in 2021, then plunged by 138.96% to -$90000.0 in 2022, then surged by 432.22% to $299000.0 in 2023, then jumped by 558.86% to $2.0 million in 2024, then declined by 15.69% to $1.7 million in 2025.
- Business Quant data shows JSPR's Share-based Compensation at $1.7 million in Q4 2025, $10.7 million in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | Jasper Therapeutics | 20.07 Mn | 20.07 Mn | - | 4.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.66 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 10.70 Mn |
| Sep 30, 2025 | 10.70 Mn |
| Jun 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.82 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Sep 30, 2024 | 2.00 Mn |
| Sep 30, 2024 | 2.00 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Dec 31, 2023 | 299,000.00 |
| Dec 31, 2023 | 299,000.00 |
| Sep 30, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.40 Mn |